Related Experiment Video
Updated: Apr 10, 2026

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device
Published on: July 20, 2022
Disseminated Streptococcus pneumoniae infection involving a ventricular assist device
J S Reeves1, N Rajagopalan2, M A Huaman1
1Division of Infectious Diseases, University of Kentucky College of Medicine, Lexington, Kentucky, USA.
Abstract:
We describe the first reported case, to our knowledge, of disseminated pneumococcal infection involving a left ventricular assist device (LVAD). The management of this infection was extremely challenging, requiring multiple surgical debridements, LVAD removal, and prolonged courses of antibiotics. The Streptococcus pneumoniae isolate was found to be serotype 19F, which is included in both the pneumococcal polysaccharide and conjugate vaccines. This report highlights the importance of routine screening for up-to-date vaccination in patients who undergo LVAD implantation.
Insights
Disseminated pneumococcal infection involving a left ventricular assist device (LVAD) is rare and challenging to manage. Routine vaccination screening is crucial for patients receiving LVADs to prevent severe Streptococcus pneumoniae infections.
Area of Science:
- Cardiology
- Infectious Diseases
- Medical Devices
Background:
- Left ventricular assist devices (LVADs) are critical for end-stage heart failure management.
- Infections associated with LVADs pose significant treatment challenges.
- Pneumococcal infections, caused by Streptococcus pneumoniae, can lead to severe systemic illness.
Observation:
- This case report details the first known instance of disseminated pneumococcal infection in a patient with an LVAD.
- The infection required extensive interventions, including multiple surgical debridements and LVAD explantation.
- The identified Streptococcus pneumoniae isolate was serotype 19F, a strain covered by current pneumococcal vaccines.
Findings:
- Disseminated pneumococcal infection in LVAD recipients is a rare but serious complication.
- Management necessitates aggressive surgical and antibiotic strategies.
- Vaccine-preventable serotypes can still cause invasive disease in vulnerable populations.
Implications:
- Highlights the critical need for comprehensive vaccination status assessment in LVAD candidates.
- Emphasizes the importance of considering pneumococcal infection in febrile LVAD patients.
- Underscores the ongoing challenge of preventing device-related infections despite vaccination efforts.
More Related Videos
Related Concept Videos
Pneumonia III: Complications and Assessment
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia II: Pathophysiology
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Endocarditis IV: Nursing Management
Endocarditis III: Medical Management

